Ore Pharmaceutical (GLGC) 10-Q 2005 Q2 Quarterly report

Exhibit 32

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned hereby certifies, in his capacity as an officer of Gene Logic Inc. (the “Company”), for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

• The Quarterly report of the Company on Form 10-Q for the quarterly period ended June 30, 2005 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
  
  
• The information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company.
  
  

Date:	August 8, 2005	By:	/s/ Mark D. Gessler
			Mark D. Gessler
			Chief Executive Officer

Date:	August 8, 2005	By:	/s/ Philip L. Rohrer, Jr.
			Philip L. Rohrer, Jr.
			Chief Financial Officer